Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort
- 15 October 2014
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 60 (2), 188-194
- https://doi.org/10.1093/cid/ciu786
Abstract
Bedaquiline is a new antibiotic that was approved for the treatment of multidrug-resistant (MDR) tuberculosis. We aimed to evaluate the short-term microbiological efficacy and the tolerability profile of bedaquiline. We performed a retrospective cohort study among patients with MDR tuberculosis receiving bedaquiline for compassionate use between January 2010 and July 2013 and evaluated at 6 months of bedaquiline treatment. A total of 35 patients with MDR tuberculosis were included in the study. Nineteen (54%) had extensively drug-resistant (XDR) tuberculosis, and 14 (40%) had isolates resistant to fluoroquinolones (Fqs) or second-line injectables. Bedaquiline was associated with a median of 4 (range, 2-5) other drugs, including linezolid in 33 (94%) cases. At 6 months of bedaquiline treatment, culture conversion was achieved in 28 of 29 (97%) cases with culture-positive pulmonary tuberculosis at bedaquiline initiation. Median time to culture conversion was 85 days (range, 8-235 days). Variables independently associated with culture conversion were treatment with a Fq (P = .01), absence of lung cavities (P < .001), and absence of hepatitis C virus infection (P = .001). A total of 7 patients (20%) experienced a ≥60-ms increase in QT interval, leading to bedaquiline discontinuation in 2 (6%) cases. Severe liver enzyme elevation occurred in 2 patients (6%). During the study period, 1 death (3%) occurred and was reported as unrelated to tuberculosis or antituberculosis treatment. The use of bedaquiline combined with other active drugs has the potential to achieve high culture conversion rates in complicated MDR and XDR tuberculosis cases, with a reassuring safety profile at 6 months of treatment.This publication has 26 references indexed in Scilit:
- Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomesEuropean Respiratory Journal, 2012
- Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 PatientsPLoS Medicine, 2012
- WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 updateEuropean Respiratory Journal, 2011
- Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of TuberculosisPLOS ONE, 2011
- Sterilizing Activity of R207910 (TMC207)-containing Regimens in the Murine Model of TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2009
- The Diarylquinoline TMC207 for Multidrug-Resistant TuberculosisThe New England Journal of Medicine, 2009
- Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP HomeostasisOnline Journal of Public Health Informatics, 2008
- In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase InhibitorAntimicrobial Agents and Chemotherapy, 2007
- Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment DurationAntimicrobial Agents and Chemotherapy, 2006
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005